Managed Care
Disease
Management

 

December 2007

Everyone knows about the perverse incentive of fee-for-service medicine, but that hasn’t had much effect on its use
John Carroll
Profits should increase over the next two years for plans that stay the course, but politics and rising premiums may affect long-term results
Martin Sipkoff
The United Kingdom is proving hospitable to UnitedHealth Group and Aetna, and there is business to be had elsewhere in Europe and on other continents
Tom Reinke
There are not many traditional medications in the pipeline, and those that are in development probably won’t make waves
Ed Silverman
Plans prod hospitals to do a better job of addressing problems that kill nearly 100,000 Americans a year
Lola Butcher



Departments
Editor's Memo
John Marcille
Legislation & Regulation
The Empire State’s approach to physician ratings quickly gains health plan support and consideration as a national answer
John Carroll
Medication Management
Programs that include a pharmacology benefit reap rewards for the health plan and the member. So why isn’t there 100 percent buy-in?
Martin Sipkoff
Tomorrow's Medicine
Evithrom may minimize some of the antibody production associated with bovine proteins, but the possibility of human viral infection exists
Thomas Morrow, MD
Health Plan Design
Many new programs offered by insurers bet that individuals, not employers, will one day be making the major decisions
Lola Butcher